Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypothyroxinemia Induction in GBM
NCT02654041Phase 2Terminated
- Sponsor
- Musli Thyropeutics Ltd.
- Start
- Mar 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of methimazole, liothyronine in glioblastoma multiforme (GBM), sponsored by Musli Thyropeutics Ltd.. Started Mar 2016; status: terminated.
02
Drugs
methimazoleliothyronine
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT02654041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02654041.